Introduction

V
itamin D is an important regulator of mineral and bone metabolism, and it is now appreciated that its metabolites and analogues have many other actions. Calcitriol, or 1a,25-dihydroxyvitamin D 3 [1, 25(OH) 2 D 3 ] , is the most active metabolite, with high affinity for the nuclear vitamin D receptor (VDR). (1) It is produced in the kidney by the 1a-hydroxylation of the precursor 25-hydroxyvitamin D 3 [25(OH)D 3 ] by the cytochrome P450 enzyme CYP27B1/1a-hydroxylase. (2) Hydroxylation of vitamin D metabolites at the carbon 24 position by 25-hydroxyvitamin D-24-hydroxylase (CYP24A1) is the first step in their inactivation and excretion. Basal expression of CYP24A1 is usually low but is highly induced by 1,25(OH) 2 D 3 .
(
Calcitriol has major effects in inhibiting proliferation and promoting differentiation of many cell types, especially tumor cells such as human breast cancer cells, (3) colon sarcoma cells, (4) prostate cancer cells, colorectal adenoma, and carcinoma cells. (5) Epidemiologic and experimental studies also indicate that 1,25(OH) 2 D 3 has antitumor effects (6) ; those effects are attributed to the inhibition of proliferation, (5, 7, 8) arrest of cell cycle, (3, 9) increase in apoptosis, (4, 10, 11) and induction of differentiation. (12, 13) The antiproliferative and prodifferentiation effects of 1,25(OH) 2 D 3 also have been demonstrated for some nonmalignant cell types, such as human peripheral monocytes. (14, 15) Little is known, however, about the effects of 25(OH)D 3 on cell proliferation and differentiation. In addition to kidney tubule cells, other human cells, notably osteoblasts (16) and their progenitors in the bone marrow, (17) produce 1,25(OH) 2 D 3 . Bone cells participate in vitamin D metabolism and also are targets of 1,25(OH) 2 D 3 action. (17) The differentiation of human marrow stromal cells (hMSCs, aka mesenchymal stem cells) (18) and rat osteogenic ROS 17/2 cells (19) ORIGINAL ARTICLE
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to osteoblasts is stimulated by 1,25(OH) 2 D 3 . Less is known about the effects of 25(OH)D 3 on bone cells. In recent studies with freshly isolated hMSCs from 19 subjects, 1,25(OH) 2 D 3 stimulated osteoblast differentiation in all samples, and 25(OH)D 3 did so in two-thirds of them. (17) The variability in response to 25(OH)D 3 may be due to differences in expression of CYP27B1. The combined presence of CYP27B1 and VDR indicates possible autocrine/paracrine roles for 25(OH)D 3 in hMSCs. This study tests the hypothesis that the antiproliferative and prodifferentiation effects of 25(OH)D 3 in hMSCs depend on CYP27B1.
Materials and Methods
Cells and reagents
Bone marrow samples were obtained with institutional review board approval as femoral tissue discarded during primary hip arthroplasty for osteoarthritis. A series of samples from 22 subjects (average age is 58 AE 15 years) was prepared and screened. Low-density marrow mononuclear cells were isolated by centrifugation on Ficoll/Histopaque 1077 (Sigma, St Louis, MO, USA). (20) This procedure removes differentiated cells and enriches for undifferentiated low-density marrow mononuclear cells that include a population of nonadherent hematopoietic cells and a fraction capable of adherence and differentiation into musculoskeletal cells. The nonadherent hematopoietic stem cells were rinsed away 24 hours after seeding, and the adherent hMSCs were expanded in monolayer culture with standard growth medium, phenol red-free a modified essential medium a-MEM), 10% fetal bovine serum-heat inactivated (FBS-HI), 100 U/mL of penicillin, and 100 mg/mL of streptomycin (Invitrogen, Carlsbad, CA, USA). All samples were used at passages 2 through 4. Some experiments used standard osteogenic medium (ie, phenol red-free a-MEM, 10% FBS-HI, 100 U/mL of penicillin, 100 mg/mL of streptomycin, 10 nM dexamethasone, 5 mM b-glycerophosphate, and 50 mg/mL of ascorbate-2-phosphate) or osteogenic medium (ie, phenol red-free a-MEM, 1% FBS-HI, 100 U/mL of penicillin, 100 mg/mL of streptomycin, 10 nM dexamethasone, 5 mM b-glycerophosphate, and 50 mg/mL of ascorbate-2-phosphate). After transfection with siRNA, all media used were without 100 U/mL of penicillin and 100 mg/mL of streptomycin. 
RNA isolation and RT-PCR
Total RNA was isolated from human MSCs with TRIZOL reagent (Invitrogen). For reverse-transcriptase polymerase chain reaction (RT-PCR), 2 mg of total RNA was reverse-transcribed into cDNA with SuperScript II (Invitrogen) following the manufacturer's instructions. Concentrations of cDNA and amplification conditions were optimized for each gene product to reflect the exponential phase of amplification. One-twentieth of the cDNA was used in each 50-mL PCR reaction (30 to 40 cycles of 948C for 1 minute, 55 to 608C for 1 minute, and 728C for 2 minutes), as described previously. (20) Gene-specific primer pairs (Table 1) for CYP27B1, (17) CYP24A1, (17) VDR, (17) Cbfa1/Runx2 (Runx2), (21) AlkP, (21) bone sialoprotein (BSP), (21) Bax, (21) and Bcl-2 (22) were used for amplification. PCR products were separated by agarose gel electrophoresis and were quantified by densitometry of captured gel images with a Kodak Gel Logic 200 Imaging System and Kodak Molecular Imaging Software following the manufacturer's instructions (Kodak Molecular Imaging Systems, 
Western immunoblot
Human MSCs were cultured in 100-mm dishes in standard growth medium (10% FBS-HI). At 50% confluence, the cells were treated with 1, 10, 100 nM 1,25(OH) 2 D 3 or 1000 nM 25(OH)D 3 for 3 days. Whole-cell lysates were prepared with lysis buffer (150 mM NaCl, 3 mM NaHCO 3 , 0.1% Triton X-100, and a mixture of protease inhibitors; Roche Diagnostics, Mannheim, Germany) and were homogenized with a pestle (Kontes, Vineland, NJ, USA) and centrifuged at 16,000g (Eppendorf centrifuge; Eppendorf, Hamburg, Germany). Protein concentration was determined (BCA system; Thermo Fisher Scientific). Western immunoblotting was performed as described previously. (20) In brief, proteins were resolved on 4% to 12% SDS-PAGE (NuPAGE Bis-Tris gel; Invitrogen) and transferred onto polyvinylidene fluoride membranes (PVDF; Amersham Biosciences, Piscataway, NJ, USA). The membranes were blocked with 5% nonfat milk in PBS buffer containing 0.1% Tween-20 (PBST) for 2 to 3 hours at room temperature and incubated at 48C overnight with primary antibodies proliferating cell nuclear antigen (PCNA) (1:3000; Abcam, Cambridge, UK), CYP27B1 (H-90, 1:1000; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), b-actin (1:8000, Santa Cruz Biotechnology, Inc.), and Bax, Bcl-2, p21
Waf1/Cip1
, and cyclin D1 (each at 1:1000; Cell Signaling Technology, Beverly, MA, USA).
After removal of the unbound primary antibodies by three 5-minute washes with PBST, the membranes were incubated with horseradish peroxidase-conjugated secondary antibodies (1:5000) for 1 hour at room temperature and washed three times for 5 minutes with PBST. The antibody-associated protein bands were revealed with the ECL-plus Western blotting system (Amersham Biosciences).
Alkaline phosphatase (AlkP) enzymatic activity assay For AlkP enzymatic activity assay, the concentration of serum in standard osteogenic medium (10% FBS-HI) was reduced to 1% FBS-HI to minimize possible subsequent differences in proliferation that could confound interpretation of the effects of vitamin D metabolites on osteoblastogenesis. The medium was changed every 2 days. AlkP enzyme activity was measured spectrophotometrically, as described previously. (21) Protein concentration was determined with the BCA system (Thermo Fisher Scientific, Inc.). The AlkP enzyme activity was expressed as micromoles per minute per gram of protein, and some was calculated as the ratio of treated relative to control.
RNA interference with CYP27B1 siRNA was a dose-dependent inhibition of proliferation with 1,25(OH) 2 D 3 for both cell preparations (Fig. 2B) , the Bax/Bcl-2 ratio was lower with 100 nM 1,25(OH) 2 D 3 (19%), but there was essentially no effect by 25(OH)D 3 (95%). The effects on mRNA levels of Bax and Bcl-2 (Fig. 3B ) corresponded with the changes observed for protein levels (Fig. 3A) .
As a second approach, the cytochrome P450 inhibitor ketoconazole was used to determine the importance of hydroxylation on 25(OH)D 3 effects on proliferation. Ketoconazole (10 mM) diminished the effects of 25(OH)D 3 (1000 nM) and not the effects of 1,25(OH) 2 D 3 (10 nM) on Bax and Bcl-2 in hMSCs hi-1a (Fig. 3C ). In the presence of 25(OH)D 3 , the Bax/Bcl-2 ratio was 27% of that with vehicle control, and the decrease by 25(OH)D 3 was blocked by ketoconazole (90%). In the presence of 1,25(OH) 2 D 3 , the Bax/Bcl-2 ratio was 36% of that with vehicle control, similar to that with 1,25(OH) 2 D 3 and ketoconazole (37%).
Relative effects of 25(OH)D 3 and 1,25(OH) 2 D 3 on osteoblast differentiation in hMSCs
Regulation of osteoblast differentiation was quantified first by AlkP enzymatic activity assays in osteogenic medium with 1% FBS-HI (Fig. 4A) Osteoblast differentiation was also monitored by osteoblast signature genes (ie, Runx2, AlkP, and BSP) after transfer to standard osteogenic medium (10% FBS-HI) or after addition of 1,25(OH) 2 D 3 to standard growth medium (10% FBS-HI). As expected, there was time-dependent upregulation of Runx2, AlkP, and BSP in hMSCs hi-1a in standard osteogenic medium (Fig. 4B) . Addition of 1,25(OH) 2 D 3 to standard growth medium also upregulated osteoblast genes in hMSCs hi-1a (Fig. 4C) .
Addition of 25(OH)D 3 to standard growth medium also upregulated osteoblast genes in hMSCs hi-1a , but its effect was diminished by ketoconazole (Fig. 4D) .
Effect of CYP27B1 siRNA on the stimulation of osteoblast differentiation by 25(OH)D 3
As another approach to assess the mechanism by which 25(OH)D 3 can stimulate osteoblast differentiation, hMSCs hi-1a were engineered to have reduced constitutive expression of CYP27B1. There were no noticeable differences in cell density or appearance of control cells (electroporation with PBS), cells treated with nonsilencing control siRNA, and cells with 10 or 100 pmol CYP27B1 siRNA (Fig. 5A ). Transient transfection of CYP27B1 siRNA into hMSCs hi-1a resulted in reductions of CYP27B1 mRNA (2% of control; Fig. 5B ) and CYP27B1 protein (11% of control; Fig. 5C ). No effect was shown with a nonsilencing, scrambled siRNA sequence (lane NC in Fig. 5B, C) . transfected with CYP27B1 siRNA, however, 25(OH)D 3 had no effect on osteoblast genes (Fig. 5E) . As a functional marker of osteoblast differentiation, we measured AlkP enzymatic activity after 7 days in osteogenic medium (1% FBS-HI). Whereas 25(OH)D 3 stimulated AlkP activity of control cells (1.87-fold, p < .0001), there was no effect in cells transfected with CYP27B1 siRNA (1.04-fold, p ¼ .093; Fig. 5F ).
Discussion
This study used three approaches to examine the role of CYP27B1 on the effects of 25(OH)D 3 in hMSCs. First, we compared cells with high and low constitutive expression of CYP27B1. Finding a wide range of expression in hMSCs from 22 subjects is consistent with our previous studies. (17) The level of CYP27B1 expression was found to be related to the vitamin D status (17) and, more recently, to age (25) of the subjects. There is growing evidence that hMSCs (17) and human bone cells (26) are both sources and targets of 1,25(OH) 2 D 3 , and thus vitamin D may have multiple autocrine/paracrine actions in bones. It was important to control for 24-hydroxylation in these studies because differences in inactivation of added vitamin D metabolites could confound interpretation. The activities of CYP27B1 and CYP24A1 are important for the maintenance of appropriate levels of 1,25(OH) 2 D 3 and 25(OH)D 3 . Therefore, two hMSCs were selected and studied in detail on the basis of having extremes in expression of CYP27B1 and equivalent expression of CYP24A1 and VDR. Further, the expression of CYP24A1 was found to be regulated with equivalence in both specimens of hMSCs; this observation reduces concerns of confounding effects of 24-hydroxylation in these studies. In addition, fresh metabolites were added daily. There were substantial differences in the synthesis of 1,25(OH) 2 (4, 10, 33) Ketoconazole is a strong but differential inhibitor of both CYP24A1 and CYP27B1 (43) and may be cytotoxic for some cells. (23) (23, 44) In conclusion, 25(OH)D 3 has multiple effects in normal hMSCs; it inhibits proliferation and promotes osteoblast differentiation by mechanisms similar to those for 1,25(OH) 2 D 3 . Our data indicate that antiproliferative and prodifferentiation effects of 25(OH)D 3 in hMSCs require 1a-hydroxylase. There are suggestions that other effects of 25(OH)D 3 in other cell types, such as induction of 24-hydroxylase in prostatic cells, may not require 1a-hydroxylase. (45) Three lines of evidence indicate that CYP27B1
is required for the effects of 25(OH)D 3 on hMSCs. Those effects were not seen (1) in hMSCs with low constitutive expression of CYP27B1, (2) in hMSCs treated with ketoconazole, or (3) in hMSCs in which CYP27B1 expression was silenced. These findings suggest that local osteoblast differentiation in vivo may be promoted by 25(OH)D 3 if the progenitor/precursor cells in marrow express CYP27B1/1a-hydroxylase. We found that many of hMSCs' in vitro behaviors and baseline characteristics depend on clinical features of the subjects from whom the cells were isolated. The level of CYP27B1 expression in those cells depends on vitamin D status and can be regulated by a number of factors, including vitamin D. (17) The combined presence of CYP27B1 and the VDR in hMSCs indicates possible autocrine/paracrine roles for 25(OH)D 3 to regulate osteoblast differentiation and skeletal homeostasis.
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